Intermittent fasting (IF) raises intracellular NAD+ levels, activating SIRT1, which deacetylates the NF‑κB p65 subunit. This reduces NF‑κB transcriptional activity, attenuates NLRP3 inflammasome priming, and permits SIRT1‑dependent deacetylation of histones at exhaustion loci (TOX, NR4A), thereby resetting chromatin to a less repressed state and restoring cytotoxic function in aged CD8+ T cells.

Rationale

• The NF‑κB/NLRP3 circuit sustains IL‑6/TNF‑α production and drives T‑cell exhaustion through checkpoint upregulation and metabolic dysfunction【NF‑κB primes NLRP3 inflammasome activation】.
• NIK deficiency in CD8+ T cells increases PD‑1/Tim3 expression and apoptosis, indicating basal NF‑κB activity is required to prevent terminal exhaustion【NIK deficiency increases PD1/Tim3】.
• p62/SQSTM1 promotes mitophagy to restrain NLRP3; its loss worsens IL‑1β inflammation【p62 induces mitophagy】.
• NAD+/SIRT1 signaling is known to deacetylate p65, suppressing NF‑κB‑driven transcription【SIRT1 deacetylates p65】.
• SIRT1 also deacetylates histone H3K9ac at promoters of exhaustion‑associated genes, facilitating a more open chromatin state【SIRT1 chromatin remodeling】.

Novel Mechanistic Insight

We propose that IF‑induced NAD+ boost does not merely dampen NF‑κB activity transiently; it triggers a SIRT1‑dependent epigenetic reset that erases repressive marks laid down by chronic NLRP3‑driven SASP. Specifically, SIRT1 deacetylates H3K27ac at enhancers of TOX and NR4A, reducing their expression and allowing transcription factors like T‑bet to re‑engage effector programs. This dual action—signaling inhibition plus chromatin remodeling—creates a bistable switch that can push exhausted T cells back toward a functional, metabolically flexible state even after checkpoint protein accumulation.

Testable Predictions

1. In vivo: Aged mice subjected to 24‑hour IF cycles twice weekly for 8 weeks will show increased NAD+ in CD8+ T cells, elevated SIRT1 activity, reduced p65 acetylation (measured by acetyl‑p65 flow), decreased NLRP3 inflammasome activation (ASC speck formation), and lower IL‑1β/IL‑6 in serum compared with ad libitum fed controls.
2. Ex vivo: Isolation of CD8+ T cells from IF‑treated mice will demonstrate decreased TOX and NR4A mRNA, increased H3K27ac loss at their promoters (ChIP‑qPCR), and restored glycolysis and IFN‑γ production upon antigenic stimulation despite unchanged PD‑1/Tim3 surface levels.
3. Human correlate: Peripheral blood from older adults undergoing a supervised IF regimen (e.g., 5:2 diet) will exhibit higher sirtuin activity in PBMCs, lower soluble PD‑1 (sPD‑1) and inflammasome markers (caspase‑1 activity), and an improved exhaustion‑reversal score (ratio of IFN‑γ+ to PD‑1+Tim3+ CD8+ T cells).

Falsifiability

If IF fails to raise NAD+/SIRT1 activity in CD8+ T cells, or if SIRT1 inhibition (using EX‑527) abolishes the improvements in exhaustion markers and metabolic function despite IF, the hypothesis is refuted. Likewise, if chromatin marks at TOX/NR4A remain unchanged while NF‑κB signaling is suppressed, the epigenetic reset mechanism would be unsupported.

Experimental Design Overview

• Animal model: C57BL/6 mice, 20 months old, randomized to IF or control diet.
• Interventions: 24‑hour fast twice weekly; optional SIRT1 inhibitor arm.
• Readouts: NAD+ quantification (LC‑MS), SIRT1 activity assay, acetyl‑p65 (Western), NLRP3 activation (ASC speck microscopy), cytokine ELISA, scRNA‑seq for exhaustion signatures, ATAC‑seq/ChIP‑seq for H3K27ac at TOX/NR4A, Seahorse glycolysis assay, intracellular IFN‑γ staining.
• Human pilot: 30 participants aged 60‑75, 12‑week 5:2 IF vs. usual diet, PBMC sampling at baseline, 6 weeks, 12 weeks.

Potential Impact

Demonstrating that a simple, non‑pharmacological regimen can break the NF‑κB/NLRP3 inflammasome loop and erase epigenetic exhaustion would define a concrete, reversible window before terminal T‑cell dysfunction becomes fixed. This would shift the field from lifespan‑extending modulators to direct damage‑repair strategies for immune aging, informing clinical trial design for NAD+ boosters or timed fasting interventions in older adults or cancer patients undergoing immunotherapy.